Intervention not reported
Sensitivities 43% and 100% · children evaluated in inpatient or outpatient settings Index tests: Xpert MTB/RIF Role: an initial test Threshold for index tests: an…
1 finding from 1 review
Intervention not reported
Xpert MTB/RIF, people living with HIV · people living with HIV and non‐hospitalized people in high‐risk groups
1 finding from 1 review
Intervention not reported
Xpert Ultra, people living with HIV · people living with HIV and non‐hospitalized people in high‐risk groups
1 finding from 1 review
Intervention not reported
Xpert MTB/RIF, non‐hospitalized people in high‐risk groups · people living with HIV and non‐hospitalized people in high‐risk groups
1 finding from 1 review
Intervention not reported
Index test · people in high‐risk groups
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Xpert MTB/RIF · people in high‐risk groups
1 finding from 1 review
Major bleedingd (3 months) · participants who sustained multiple traumatic injuriesa
1 finding from 1 review
Mortality (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in mortality (up to 6 months) compared with anticoagulation (moderate certainty).
1 finding from 1 review
Symtomatic lower extremity venous thrombosis confirmed by Doppler ultrasound or venography (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in symtomatic lower extremity venous thrombosis confirmed by Doppler… compared with anticoagulation (moderate certainty).
1 finding from 1 review
Filter‐related complications (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
1 finding from 1 review
Major bleeding · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in major bleedingc (up to 6 months) compared with anticoagulation (moderate certainty).
1 finding from 1 review
Mortality from any cause (up to 90 days) · participants who sustained multiple traumatic injuriesa
1 finding from 1 review
Lower extremity venous thrombosis confirmed by Doppler ultrasound or venography (at 14 days) · participants who sustained multiple traumatic injuriesa
1 finding from 1 review
Filter‐related complications (up to 232 days) · participants who sustained multiple traumatic injuriesa
1 finding from 1 review
Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).
1 finding from 1 review
Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection
Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).
1 finding from 1 review
QoL · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
FEV1 % predicted · adults and children with cystic fibrosis
Summary of findings: β‐carotene showed no clear difference in respiratory function absolute FEV1 % predicted compared with placebo (low certainty).
1 finding from 1 review
Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review